- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease
- Interventions
- Etelcalcetide, Standard of Care
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Kansas City, Missouri + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 67
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
- Interventions
- PLS240, Placebo, Open-Label Extension PLS240
- Drug
- Lead sponsor
- Pathalys Pharma
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 362 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 49
- States / cities
- Pine Bluff, Arkansas • Anaheim, California • Beverly Hills, California + 41 more
- Conditions
- Hyperparathyroidism, Secondary
- Interventions
- Etelcalcetide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 891 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 86 more
- Conditions
- Chronic Kidney Disease, Stage 5, Secondary Hyperparathyroidism
- Interventions
- Zemplar® injection, Hectorol® injection
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 2
- States / cities
- Bellevue, Nebraska • Omaha, Nebraska
- Conditions
- Hyperparathyroidism, Chronic Kidney Disease
- Interventions
- sevelamer carbonate, placebo
- Drug
- Lead sponsor
- Kenneth R. Phelps, M.D.
- Individual
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Albany, New York
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary
- Interventions
- Cinacalcet hydrochloride, Standard of Care
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 28 Days to 2189 Days
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- Hectorol (doxercalciferol capsules), Zemplar (paricalcitol injection)
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 8
- States / cities
- Downey, California • Paramount, California • Hudson, Florida + 5 more
- Conditions
- Secondary Hyperparathyroidism, End Stage Renal Disease
- Interventions
- paricalcitol injection
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 6
- States / cities
- Stanford, California • Miami, Florida • Buffalo, New York + 2 more
- Conditions
- Renal Osteodystrophy, Chronic Kidney Diseases, CKD-MBD, Bone Turnover Rate Disorder, Secondary Hyperparathyroidism
- Interventions
- miRNAseq analysis, Standard treatment for bone disorder
- Procedure · Drug
- Lead sponsor
- Thomas Nickolas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
- Interventions
- CTA018 Injection
- Drug
- Lead sponsor
- OPKO IP Holdings II, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 5
- States / cities
- Pembroke Pines, Florida • Meridian, Idaho • Springfield, Massachusetts + 2 more
- Conditions
- Hyperparathyroidism, Secondary
- Interventions
- Etelcalcetide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 902 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Alhambra, California • Azusa, California + 64 more
- Conditions
- Hyperparathyroidism, Secondary
- Interventions
- Etelcalcetide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 45
- States / cities
- Mobile, Alabama • Azusa, California • Beverly Hills, California + 42 more
- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease
- Interventions
- Zemplar, 42 Ca carbonate absorption via single tracer method, Calcijex
- Drug · Procedure
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Kidney Disease
- Interventions
- Vitamin D, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Atlanta VA Medical Center
- Federal
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism
- Interventions
- Contrast Enhanced Ultrasonography
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Chronic Kidney Disease
- Interventions
- Calcium acetate, Lanthanum Carbonate, Sevelamer Carbonate, Placebo
- Drug
- Lead sponsor
- Denver Nephrologists, P.C.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Vitamin D Insufficiency
- Interventions
- Cohort 1 CTAP101 Capsules- 60µg, Cohort 1 CTAP101 Capsules - 90µg, Cohort 1 Matching Sugar Capsule, Cohort 2 CTAP101 Capsules - 30µg, Cohort 2 Matching Sugar Capsule
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Bannockburn, Illinois
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
- Interventions
- CTAP201 Injection, Doxercalciferol
- Drug
- Lead sponsor
- OPKO IP Holdings II, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 6
- States / cities
- Peoria, Arizona • Springfield, Massachusetts • Cincinnati, Ohio + 3 more
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Disease, Secondary Hyperparathyroidism
- Interventions
- cinacalcet capsule, placebo, Standard of Care
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis
- Interventions
- Paricalcitol, Cinacalcet
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 30
- States / cities
- Tempe, Arizona • Chula Vista, California • Los Angeles, California + 22 more
- Conditions
- Hyperparathyroidism, Secondary, Kidney Failure, Chronic
- Interventions
- DP001 softgel capsules, Placebo
- Drug
- Lead sponsor
- Deltanoid Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 11 more
- Conditions
- Kidney Failure, Chronic, Chronic Kidney Disease-Mineral and Bone Disorder
- Interventions
- Oral calcitriol with cinacalcet rescue, IV activated vitamin D
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
- Interventions
- Paricalcitol
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 0 Years to 9 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Redwood City, California • Washington D.C., District of Columbia + 10 more
- Conditions
- Renal Osteodystrophy, End Stage Renal Disease
- Interventions
- calcitriol, growth hormone
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 1
- States / cities
- Los Angeles, California